Meridian Launches New Range of Lyo-Ready PCR Mixes
Source: Nasdaq GlobeNewswire / 07 Feb 2019 07:30:15 America/New_York
CINCINNATI, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to introduce its next-generation lyophilization-ready mixes for one-step RT-qPCR. These master mixes offer new solutions for developing freeze-dried multiplex assays that can simultaneously detect both RNA and DNA viruses.
Lyo-Ready One-Step RT-qPCR and Lyo-Ready One-Step Viral RT-qPCR are glycerol-free formulations that contain optimized lyophilization excipients, which have been tested with a range of lyophilization protocols and formats, including cakes and beads. Their high performance in multiplex reactions in combination with very fast rehydration times, make them ideally suited for automated high-throughput platforms. Lyo-Ready One-Step Viral RT-qPCR has been specifically developed for amplification of RNA viruses with a high secondary structure.
Molecular diagnostic tests are progressively moving towards a lyophilized format in order to avoid the need for a cool chain, leading to considerable cost savings during shipment and storage. However, there are significant technical challenges in developing an RT-qPCR lyophilization-compatible mix that has the same highly reproducible performance as a ‘wet’ formulation. Building on its expertise in the field of PCR, the life science division of Meridian Bioscience has successfully developed a range of ready-to-use, lyophilization-compatible products to suit this growing demand within the molecular diagnostics industry.
Dr. Lourdes Weltzien, Executive Vice President of Life Science, commented, “We are delighted to announce the release of our new Lyo-Ready One-Step RT-qPCR master mixes. We now have a range of ready-to-use, lyophilization-friendly solutions for our IVD and biotech customers looking to improve the accuracy of their assays, increase operational efficiencies and reduce their overall costs. We remain committed to bringing innovation and quality products to the IVD community.”
For complete information, please visit meridianlifescience.com/molecular-dx-reagents.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
Chief Executive Officer
Meridian Bioscience, Inc.